<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cinacalcet: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cinacalcet: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cinacalcet: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11704" href="/d/html/11704.html" rel="external">see "Cinacalcet: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="122817" href="/d/html/122817.html" rel="external">see "Cinacalcet: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F151617"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sensipar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866346"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Cinacalcet;</li>
<li>AURO-Cinacalcet;</li>
<li>JAMP Cinacalcet;</li>
<li>M-Cinacalcet;</li>
<li>MAR-Cinacalcet;</li>
<li>MYLAN-Cinacalcet;</li>
<li>PMS-Cinacalcet;</li>
<li>PRIVA-Cinacalcet [DSC];</li>
<li>Sensipar;</li>
<li>TEVA-Cinacalcet</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F151636"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Calcimimetic</li></ul></div>
<div class="block doa drugH1Div" id="F151619"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fcbbef9-09cd-4905-b48e-659a1b46ef37">Hyperparathyroidism, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperparathyroidism, primary:</b>
<b>Oral:</b> Initial: 30 mg twice daily; may increase dose incrementally (to 60 mg twice daily, 90 mg twice daily, and 90 mg 3 or 4 times daily) every 2 to 4 weeks as necessary to normalize serum calcium levels.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e82cf5eb-15af-476a-ad95-f09f01a8c86e">Hyperparathyroidism, secondary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperparathyroidism, secondary (dialysis-dependent chronic kidney disease):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In patients with severely elevated parathyroid hormone (PTH) levels (eg, &gt;800 pg/mL), cinacalcet monotherapy may be inadequate to achieve target PTH levels; combination therapy (eg, with calcitriol or vitamin D analogs and/or phosphate binders) may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420','lexi-content-ref-25904755','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420','lexi-content-ref-25904755','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 30 mg once daily; may increase dose in 30 mg/day increments every 2 to 4 weeks up to 180 mg once daily as necessary to maintain target PTH levels.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Conversion from etelcalcetide</b>
<b>:</b> Discontinue etelcalcetide for at least 4 weeks prior to initiating cinacalcet.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f151ff12-8aaa-4762-b00f-ea7d52d3ee76">Parathyroid carcinoma, hypercalcemia treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parathyroid carcinoma, hypercalcemia treatment:</b>
<b>Oral:</b> Initial: 30 mg twice daily; may increase dose incrementally (to 60 mg twice daily, 90 mg twice daily, and 90 mg 3 to 4 times daily) every 2 to 4 weeks as necessary to normalize serum calcium levels.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991216"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15871636','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15871636','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15871636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15871636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15871636','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15871636','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988422"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Pugh class B or C): There are no specific dosage adjustments provided in the manufacturer's labeling; exposure and half-life of cinacalcet is increased. Dosage adjustments may be necessary based on serum calcium, phosphorus, and/or parathyroid hormone levels.</p></div>
<div class="block dot drugH1Div" id="F151637"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for low parathyroid hormone levels:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Parathyroid hormone &lt;150 pg/mL: Reduce dose or discontinue cinacalcet and/or vitamin D analog.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for hypocalcemia (patients with secondary hyperparathyroidism)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">If serum calcium &gt;7.5 mg/dL but &lt;8.4 mg/dL (&gt;1.87 mmol/L but &lt;2.1 mmol/L) and continuation of cinacalcet is desired: Mild (eg, serum calcium 8 to &lt;8.4 mg/dL [2 to &lt;2.1 mmol/L]) or asymptomatic hypocalcemia due to cinacalcet may not require treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29525393','lexi-content-ref-30675420','lexi-content-ref-31848883','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29525393','lexi-content-ref-30675420','lexi-content-ref-31848883','lexi-content-ref-Manu.1'])">Ref</a></span>). In patients with more significant or symptomatic hypocalcemia, may consider use of calcium-containing phosphate binders, use of vitamin D analogs, and/or adjustment of dialysate calcium content to raise calcium levels while avoiding hypercalcemia.</p>
<p style="text-indent:-2em;margin-left:4em;">If serum calcium &lt;7.5 mg/dL (&lt;1.87 mmol/L) <b>or</b> if hypocalcemia symptoms persist despite treatment: Withhold cinacalcet until serum calcium ≥8 mg/dL (≥2 mmol/L) and/or symptoms of hypocalcemia resolve. Reinitiate cinacalcet at the next lowest dose.</p></div>
<div class="block doe drugH1Div" id="F151620"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53211876"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="122817" href="/d/html/122817.html" rel="external">see "Cinacalcet: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e82cf5eb-15af-476a-ad95-f09f01a8c86e">Hyperparathyroidism, secondary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperparathyroidism, secondary: Note:</b> Should only be used when standard therapies have proven ineffective. Ensure calcium is in normal range before initiating therapy and monitor closely throughout treatment. Dosing based on patient's dry weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Limited data available, optimal dosage not established in pediatric patients: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Initial: ≤0.2 mg/kg/dose once daily; may titrate every 4 weeks to reach target range of intact parathyroid hormone (iPTH) of 100 to 300 pg/mL. Maximum daily dose: 180 mg/<b>day</b> or 2.5 mg/kg/dose (whichever is lower) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30506144','lexi-content-ref-Mimpara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30506144','lexi-content-ref-Mimpara.1'])">Ref</a></span>). Dosing based on a randomized, double-blind study (n=43) with an open-label phase (n=12) with secondary hyperparathyroidism on hemodialysis or peritoneal dialysis. Cinacalcet was started at ≤0.2 mg/kg/day in 22 patients (mean age: 13.3 ± 3.6 years) and titrated every 4 weeks to goal iPTH. For the efficacy endpoint phase, the mean weight adjusted dose was 1.54 mg/kg/day which corresponded to 50.4 mg/day. iPTH was decreased by ≥30% in 54% of patients receiving cinacalcet compared to 19% with placebo. Serum calcium was significantly reduced in patients receiving cinacalcet compared to placebo and severe hypocalcemia (&lt;7.5 mg/dL) occurred in 3 patients, including 1 death where treatment-related cause could not be ruled out (corrected calcium was 5.3 mg/dL). This study was placed on hold following the reported death and ultimately terminated after 14 months. Despite the limited number of patients enrolled due to study termination, efficacy was still demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30506144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30506144'])">Ref</a></span>). <b>Note:</b> Cinacalcet use in children &lt;3 years and infants as young as 8 months has been described; however, variable dosing strategies were used or only single doses were administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18504621','lexi-content-ref-19838738','lexi-content-ref-30141180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18504621','lexi-content-ref-19838738','lexi-content-ref-30141180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-band (fixed) dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mimpara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mimpara.1'])">Ref</a></span>):</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Weight Band</p></th>
<th align="center">
<p style="text-indent:0em;">Initial Dose</p></th>
<th align="center">
<p style="text-indent:0em;">Suggested Adjustment Doses</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">≥10 to &lt;12.5 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥12.5 to &lt;25 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.5 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥25 to &lt;36 kg</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg, 10 mg, 15 mg, 30 mg, 60 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥36 to &lt;50 kg</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg, 10 mg, 15 mg, 30 mg, 60 mg, 90 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥50 to &lt;75 kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg, 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥75 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg, 30 mg, 60 mg, 90 mg, 120 mg, 180 mg</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment for hypocalcemia </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mimpara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mimpara.1'])">Ref</a></span>): Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Corrected serum calcium at or below age-specific lower limit <b>or</b> symptoms of hypocalcemia (regardless of calcium concentration):</i> Temporarily discontinue cinacalcet and administer calcium supplements, calcium-containing phosphate binders, and/or vitamin D to raise calcium.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Corrected serum calcium above age-specific lower limit<b> and </b>resolution of hypocalcemia symptoms:</i> Re-initiate cinacalcet at a lower dose. If treatment is stopped for ≥14 days, restart at initial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose adjustment based on iPTH</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mimpara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mimpara.1'])">Ref</a></span>): Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">If iPTH is ≥100 to &lt;150 pg/mL: Reduce dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If iPTH &lt;100 pg/mL: Discontinue cinacalcet until iPTH is &gt;150 pg/mL; restart at lower dose; if treatment has been stopped for &gt;14 days, restart at initial dose.</p></div>
<div class="block dorp drugH1Div" id="F53211879"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments in the manufacturer's labeling; however, adjustment is unnecessary as cinacalcet is indicated for use in chronic kidney disease.</p></div>
<div class="block dohp drugH1Div" id="F53211880"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments in the manufacturer's labeling; in moderate to severe impairment, dosage adjustments may be necessary based on serum calcium, serum phosphorus, and/or intact parathyroid hormone.</p></div>
<div class="block adr drugH1Div" id="F151586"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (&lt;8.4 mg/dL: 6% to 75%; &lt;7.5 mg/dL: 29% to 33%), hypoparathyroidism (intact parathyroid hormone &lt;100 pg/mL: ≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (29% to 31%), vomiting (26% to 27%), diarrhea (21%), abdominal pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (11% to 18%), myalgia (15%), back pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (13%), cough (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Upper abdominal pain (8%), dyspepsia (7%), anorexia (6%), decreased appetite (6%), constipation (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (7% to 10%), noncardiac chest pain (6%), seizure (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Upper gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Adynamic bone disease, angioedema, calcium pyrophosphate deposition disease, cardiac arrhythmia, cardiac failure, gastrointestinal hemorrhage, prolonged QT interval on ECG (secondary to hypocalcemia), skin rash, urticaria, ventricular arrhythmia (secondary to hypocalcemia)</p></div>
<div class="block coi drugH1Div" id="F151600"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serum calcium less than the lower limit of normal range</p>
<p style="text-indent:-4em;margin-left:4em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to any component of the formulation</p></div>
<div class="block war drugH1Div" id="F151584"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adynamic bone disease: May develop if parathyroid hormone levels are suppressed &lt;100 pg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: QT prolongation and ventricular arrhythmia secondary to hypocalcemia may occur. Patients with congenital long QT syndrome, history of QT interval prolongation, family history of long QT syndrome or sudden cardiac death, and other conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk. Cases of idiosyncratic hypotension, worsening of heart failure, and/or arrhythmia have been reported in patients with impaired cardiovascular function; may correlate with decreased serum calcium.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: GI bleeding, mostly upper GI bleeding, have been reported (exact cause unknown); patients with risk factors for upper GI bleeding (eg, gastritis, esophagitis, ulcers, severe vomiting) may be at increased risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Life-threatening and fatal events associated with hypocalcemia have occurred. Use with caution in patients receiving concomitant therapies known to lower serum calcium concentrations. May require treatment interruption, dose reduction, or initiation (or dose increases) of calcium-based phosphate binder and/or vitamin D to raise serum calcium depending on calcium levels or symptoms of hypocalcemia. Do not initiate therapy if the corrected serum calcium is less than the lower limit of normal; corrected serum calcium must be at or above the lower limit of normal prior to initiation, dose increase, or reinitiation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (Child-Pugh classes B and C); cinacalcet exposure and half-life are increased.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder; seizure threshold is lowered by significant serum calcium reductions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for chronic kidney disease (CKD) patients not receiving dialysis. In the United States, the long-term safety and efficacy of cinacalcet has not been evaluated in CKD patients with hyperparathyroidism not requiring dialysis. Although possibly related to lower baseline calcium levels, clinical studies have shown an increased incidence of hypocalcemia (&lt;8.4 mg/dL) in patients not requiring dialysis.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53211873"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Severe hypocalcemia has been reported in pediatric patients receiving cinacalcet; monitor serum calcium closely. During a phase 3 clinical trial in pediatric dialysis patients (n=22; mean age: 13.3 years; age range: 6 to &lt;18 years) with secondary hypoparathyroidism receiving cinacalcet, mild hypocalcemia (&lt;8.4 mg/dL) was reported in 7 patients, moderate hypocalcemia (&lt;8 mg/dL) was reported in 5 patients, and severe hypocalcemia (&lt;7.5 mg/dL) was reported in 3 patients, including 1 fatality. The patient who died had a calcium of 5.3 mg/dL; the patient death was attributed to multifactorial reasons; however, association with cinacalcet treatment could not be ruled out (Warady 2019). Asymptomatic hypocalcemia has also been reported in pediatric patients. Half of the patients enrolled in an open-label, single-dose safety, tolerability, and pharmacokinetic study (n=12) developed asymptomatic hypocalcemia; calcium concentrations ranged from 2 to 2.2 mmol/L within 12 hours post dose (Padhi 2012). In a retrospective case series (n=6), asymptomatic hypocalcemia occurred in 2 patients including 1 patient who was refractory to treatment requiring discontinuation of cinacalcet for 5 months (Platt 2010).</p></div>
<div class="block foc drugH1Div" id="F151594"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensipar: 30 mg, 60 mg, 90 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg, 90 mg</p></div>
<div class="block geq drugH1Div" id="F151582"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F151602"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cinacalcet HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $2.83 - $34.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $3.29 - $61.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $3.31 - $92.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sensipar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $32.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $64.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $96.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866347"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensipar: 30 mg, 60 mg, 90 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg, 90 mg</p></div>
<div class="block adm drugH1Div" id="F151597"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with food or shortly after a meal. Do not chew, crush, or divide tablet; administer whole.</p></div>
<div class="block admp drugH1Div" id="F53211882"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Children ≥3 years and Adolescents: Administer with food or shortly after a meal. Administer tablets whole; do not chew, crush, or divide tablets. An extemporaneous preparation may be made if patients cannot swallow tablets.</p></div>
<div class="block use drugH1Div" id="F151596"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperparathyroidism, primary:</b> Treatment of hypercalcemia in adults with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperparathyroidism, secondary:</b> Treatment of secondary hyperparathyroidism in adults with chronic kidney disease on dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parathyroid carcinoma, hypercalcemia treatment:</b> Treatment of hypercalcemia in adults with parathyroid carcinoma.</p></div>
<div class="block cyt drugH1Div" id="F151630"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>
<div class="block dri drugH1Div" id="F151588"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Amitriptyline. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amoxapine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amoxapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Atomoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose when treating indications other than major depressive disorder.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ClomiPRAMINE. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cinacalcet.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the hypocalcemic effect of Calcimimetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Dextromethorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Topical): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: Cinacalcet may enhance the hypocalcemic effect of Etelcalcetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iboga. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Imipramine. Concentrations of desipramine may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Imipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofepramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lofepramine. The active metabolite of lofepramine is desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoclopramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nortriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nortriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perhexiline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perphenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Protriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Calcimimetic Agents may increase the serum concentration of Siponimod.  Management: Coadministration of siponimod with drugs which are both moderate inhibitors of CYP2C9 and moderate or strong inhibitors of CYP3A4 is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Cinacalcet may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Trimipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F151614"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases bioavailability. Management: Administer with food or shortly after a meal.</p></div>
<div class="block pri drugH1Div" id="F151603"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to the use of cinacalcet in pregnant females is limited (Edling 2014; Horjus 2009; Nadarasa 2014; Rey 2016; Vera 2016).</p></div>
<div class="block brc drugH1Div" id="F151604"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if cinacalcet is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F151592"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs/symptoms of hypocalcemia (eg, muscle spasms, myalgia, paresthesia, seizure, tetany). In patients on concurrent strong <i>CYP3A4</i> inhibitors or with seizure disorders, closely monitor serum calcium and PTH levels. In patients with moderate to severe hepatic impairment, closely monitor serum calcium, PTH, and serum phosphorous levels. In patients at risk for GI bleeding (eg, gastritis, esophagitis, ulcers, severe vomiting), monitor for worsening of nausea and vomiting and for signs/symptoms of GI bleeding and ulceration. In patients at risk for QT prolongation, closely monitor albumin-corrected serum calcium levels and QT interval.</p>
<p style="text-indent:-2em;margin-left:2em;">Secondary hyperparathyroidism: Serum calcium and phosphorus levels prior to initiation and within a week of initiation and frequently during dose titration; parathyroid hormone (PTH) 1 to 4 weeks after initiation or dosage adjustment (wait at least 12 hours after dose before drawing PTH levels). Once maintenance dose is established, obtain serum calcium levels monthly.</p>
<p style="text-indent:-2em;margin-left:2em;">Primary hyperparathyroidism and parathyroid carcinoma: Serum calcium levels prior to initiation and within 1 week of initiation or dosage adjustment; once maintenance dose is established, obtain serum calcium every 2 months.</p></div>
<div class="block rer drugH1Div" id="F151595"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Due to the complexity and interdependency of the laboratory parameters used for therapeutic decisions in patients with chronic kidney disease-mineral and bone disorder, serial assessments of serum phosphate, calcium, and parathyroid hormone (PTH) levels should be considered together (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium (total): Normal range: Adults: 8.5 to 10.5 mg/dL (2.12 to 2.62 mmol/L) (IOM 2011). Avoid hypercalcemia for chronic kidney disease (CKD) stages G3a to G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L). Lower elevated phosphorus levels toward the normal range for CKD stages G3a to G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">PTH:</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G3a to G5: Optimal PTH level is unknown; evaluate patients with progressively elevated PTH levels or if levels are consistently above the normal range (assay-dependent) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis patients: Maintain PTH levels within 2 to 9 times the ULN for the assay used (KDIGO 2017).</p></div>
<div class="block pha drugH1Div" id="F151583"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Increases the sensitivity of the calcium-sensing receptor on the parathyroid gland thereby, concomitantly lowering parathyroid hormone (PTH), serum calcium, and serum phosphorus levels, preventing progressive bone disease and adverse events associated with mineral metabolism disorders. </p></div>
<div class="block phk drugH1Div" id="F151599"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: ~1,000 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~93% to 97% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic (extensive) via CYP3A4, 2D6, 1A2; forms inactive metabolites </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: 30 to 40 hours; moderate hepatic impairment: 65 hours; severe hepatic impairment: 84 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: ~2 to 6 hours; increased with food.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine ~80% (as metabolites); feces ~15%</p></div>
<div class="block phksp drugH1Div" id="F51220838"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with moderate or severe hepatic impairment, the AUCs were 2.4 and 4.2 times higher, respectively, than in healthy subjects; the half-life is increased to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539832"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Endolet | Glandy | Mimpara | Viscap</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Autraxil | Mimpara | Plientax | Tenalcet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet aristo | Cinacalcet Dr. Reddy's | Cinacalcet ratiopharm | Cinacalcet stada | Cinglan | Mimpara</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet mylan | Pharmacor cinacalcet | Sensipar</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet ab | Cinacalcet sandoz | Mimpara</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet heaton | Cinacalcet teva | Mimpara</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Calt | Cloridrato de cinacalcete | Mimpara | Missort</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet devatis | Cinacalcet mepha | Mimpara</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet | Citale | Driada | Geser | Mimpara</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Regpara</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cetcal | Cinacred | Cinaltius | Cinecet | Mimpara | Sinacept | Tyrocet</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet heaton | Cinacalcet stada | Cinglan | Kalten | Micalcet</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cinacabet | Cinacalcet al | Cinacalcet ascend | Cinacalcet devatis | Cinacalcet gen.orph | Cinacalcet glenmark | Cinacalcet heumann | Cinacalcet hexal | Cinacalcet medice | Cinacalcet mylan | Cinacalcet ratiopharm | Cinacalcet stada | Cinacalcet tillomed | Cinacalcet zentiva | Mimpara</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet teva | Mimpara</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet | Mimpara | Paracalcet</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet accordpharma | Cinacalcet aristo | Cinacalcet aurovitas | Cinacalcet dr reddys | Cinacalcet mylan | Cinacalcet normon | Cinacalcet sandoz | Cinacalcet stada | Cinacalcet teva | Cinacalcet tillomed | Mimpara</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet accordpharma | Cinacalcet mylan | Cinacalcet orion | Cinacalcet ratiopharm | Cinacalcet sandoz | Cinacalcet stada | Mimpara | Sinafex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet arrow | Cinacalcet biogaran | Cinacalcet eg | Cinacalcet evolugen | Cinacalcet mylan | Cinacalcet sandoz | Cinacalcet teva | Cinacalcet zentiva | Mimpara</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet | Cinacalcet accord | Cinacalcet Dr. Reddy's | Cinacalcet milpharm | Cinacalcet mylan | Cinacalcet tillomed | Cinacalcet zentiva | Mimpara</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Calcedem | Cinacalcet / faran | Cinacalcet mylan | Cinacalcet/pharmazac | Cinacalcet/rafarm | Cinacalcet/teva | Mimpara | Sensipar</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Regpara</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Mimpara | Sensipar</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet clonmel | Cinacalcet Rowex | Cinacalcet teva | Mimpara</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Capicet | Ceracal | Cinapar | Mimcina | Mimcipar | Pth | Senacept | Setz</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet aristo | Cinacalcet aurobindo | Cinacalcet doc | Cinacalcet dr reddys | Cinacalcet eg | Cinacalcet gen.orph | Cinacalcet mylan | Cinacalcet sandoz | Cinacalcet tillomed</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Mimpara</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Regpara</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Benef | Calcepara | Callegna | Cinabm | Cinacal | Cinacet | Cinapara | Legcal | Regpara | Renapara | Renaset | Repacet | Repatzin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mimpara</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet | Cinacalcet accord | Mimpara</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mimpara</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet accordpharma | Cinacalcet teva | Mimpara</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Arissa | Cinacalcet hetero | Mimpara</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mimpara | Regpara</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet amarox | Cinacalcet CF | Cinacalcet mylan | Cinacalcet teva | Cinacalcet will pharma | Mimpara</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet aristo | Cinacalcet mylan | Cinacalcet stada | Mimpara</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet devatis | Sensipar</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Geser</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Calcipar</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Mimcipar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet aurovitas | Cinacalcet bioton | Cinacalcet mylan | Cinacalcet teva | Mimpara</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet | Sensipar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accordpharma | Cinacalcet teva | Mimpara</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mimpara</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet heaton</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet | Cinacalcet tl | Mimpara | Rotocalcet</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cinac | Endolet | Glandy | Mimpara</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet accordpharma | Cinacalcet mylan | Cinacalcet orion | Cinacalcet sandoz | Cinacalcet stada | Cinacalcet teva | Mimpara</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Regpara</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cinakalcet Mylan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cinacalcet accord | Cinacalcet heaton | Cinacalcet mylan | Cinacalcet teva | Cinamed | Mimpara</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Calcelar</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Mimpara</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cineset | Cynacal | Kalsiset | Mimpara | Nefroset | Pimaro | Viscap</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cinaca | Regpara</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Sensipar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15071126">
<a name="15071126"></a>Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. <i>N Engl J Med</i>. 2004;350(15):1516-1525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/15071126/pubmed" id="15071126" target="_blank">15071126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24013984">
<a name="24013984"></a>Edling KL, Korenman SG, Janzen C, et al. A pregnant dilemma: primary hyperparathyroidism due to parathyromatosis in pregnancy. <i>Endocr Pract</i>. 2014;20(2):e14-e17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/24013984/pubmed" id="24013984" target="_blank">24013984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14520607">
<a name="14520607"></a>Eknoyan G, Levin A, and Levin NW. Bone metabolism and disease in chronic kidney disease. <i>Am J Kidney Dis. </i>2003;42(4)(suppl 3):1-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/14520607/pubmed" id="14520607" target="_blank">14520607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29525393">
<a name="29525393"></a>Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. <i>Kidney Int</i>. 2018;93(6):1475-1482. doi:10.1016/j.kint.2017.12.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/29525393/pubmed" id="29525393" target="_blank">29525393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19845125">
<a name="19845125"></a>Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. <i>J Pediatr Endocrinol Metab</i>. 2009;22(8):741-749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/19845125/pubmed" id="19845125" target="_blank">19845125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675420">
<a name="30675420"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>Kidney Int Suppl (2011)</i>. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/30675420/pubmed" id="30675420" target="_blank">30675420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31848883">
<a name="31848883"></a>Louie KS, Erhard C, Wheeler DC, Stenvinkel P, Fouqueray B, Floege J. Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. <i>J Nephrol</i>. 2020;33(4):803-816. doi:10.1007/s40620-019-00686-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/31848883/pubmed" id="31848883" target="_blank">31848883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19470620">
<a name="19470620"></a>Marcocci C, Chanson P, Shoback D, et al. Cinacalcet Reduces Serum Calcium Concentrations in Patients With Intractable Primary Hyperparathyroidism. <i>J Clin Endocrinol Metab</i>. 2009;94(8):2766-2772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/19470620/pubmed" id="19470620" target="_blank">19470620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mimpara.1">
<a name="Mimpara.1"></a>Mimpara (cinacalcet) [prescribing information]. Breda, Netherlands: Amgen Europe BV; received 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16030053">
<a name="16030053"></a>Moe SM, Cunningham J, Bommer J, et al. Long-Term Treatment of Secondary Hyperparathyroidism With the Calcimimetic Cinacalcet HCl. <i>Nephrol Dial Transplant</i>. 2005;20(10):2186-2193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/16030053/pubmed" id="16030053" target="_blank">16030053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18504621">
<a name="18504621"></a>Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. <i>Pediatr Nephrol</i>. 2008;23(10):1823-1829.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/18504621/pubmed" id="18504621" target="_blank">18504621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25298882">
<a name="25298882"></a>Nadarasa K, Bailey M, Chahal H, et al. The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. <i>Endocrinol Diabetes Metab Case Rep</i>. 2014;2014:140056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/25298882/pubmed" id="25298882" target="_blank">25298882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15871636">
<a name="15871636"></a>Padhi D, Harris RZ, Salfi M, Sullivan JT. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). <i>Clin Pharmacokinet</i>. 2005;44(5):509-516. doi:10.2165/00003088-200544050-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/15871636/pubmed" id="15871636" target="_blank">15871636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22639045">
<a name="22639045"></a>Padhi D, Langman CB, Fathallah-Shaykh S, et al. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. <i>Pediatr Nephrol</i>. 2012;27(10):1953-1959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/22639045/pubmed" id="22639045" target="_blank">22639045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19838738">
<a name="19838738"></a>Platt C, Inward C, McGraw M, et al. Middle-term use of cinacalcet in paediatric dialysis patients. <i>Pediatr Nephrol</i>. 2010;25(1):143-148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/19838738/pubmed" id="19838738" target="_blank">19838738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27761256">
<a name="27761256"></a>Rey E, Jacob CE, Koolian M, Morin F. Hypercalcemia in pregnancy — a multifaceted challenge: case reports and literature review. <i>Clin Case Rep</i>. 2016;4(10):1001-1008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/27761256/pubmed" id="27761256" target="_blank">27761256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sensipar.1">
<a name="Sensipar.1"></a>Sensipar (cinacalcet) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sensipar.2">
<a name="Sensipar.2"></a>Sensipar (cinacalcet) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17666472">
<a name="17666472"></a>Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma. <i>J Clin Endocrinol Metab</i>. 2007;92(10):3803-3808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/17666472/pubmed" id="17666472" target="_blank">17666472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30141180">
<a name="30141180"></a>Sohn WY, Portale AA, Salusky IB, et al. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to &lt;6 years with chronic kidney disease receiving dialysis. <i>Pediatr Nephrol</i>. 2019;34(1):145-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/30141180/pubmed" id="30141180" target="_blank">30141180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29691267">
<a name="29691267"></a>Thomson K, Hutchinson DJ, Chablani L. Stability of extemporaneously prepared cinacalcet oral suspensions. <i>Am J Health Syst Pharm</i>. 2018;75(9):e236-e240. doi: 10.2146/ajhp170072.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/29691267/pubmed" id="29691267" target="_blank">29691267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27998296">
<a name="27998296"></a>Vera L, Oddo S, Di Iorgi N, Bentivoglio G, Giusti M. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature. <i>J Med Case Rep</i>. 2016;10(1):361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/27998296/pubmed" id="27998296" target="_blank">27998296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30506144">
<a name="30506144"></a>Warady BA, Iles JN, Ariceta G, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. <i>Pediatr Nephrol</i>. 2019;34(3):475-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/30506144/pubmed" id="30506144" target="_blank">30506144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25904755">
<a name="25904755"></a>Wetmore JB, Gurevich K, Sprague S, et al. A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). <i>Clin J Am Soc Nephrol</i>. 2015;10(6):1031-1040. doi:10.2215/CJN.07050714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/25904755/pubmed" id="25904755" target="_blank">25904755</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8850 Version 365.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
